Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2007
September 4, 2007
- ViaCell Announces ViaCyte Collaboration with EMD Serono, Inc.
- Positive Bioequivalence Study Results Trigger Milestone Payment for Eurand
- InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
- AstraZeneca Enhances Clinical Research Capabilities in China With First Clinical Pharmacology Unit
- Pharmexa Loses European Patent Appeal for Broad Claims to Telomerase-Based Cancer Vaccines
- Shire Voluntarily Withdraws a Limited Portion of Daytrana (Methylphenidate Transdermal System) Patches
- Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
- Noven Provides Update on Daytrana Methylphenidate Transdermal System
- Canon Communications Acquires Engel Publishing Partners from Euromoney Institutional Investor PLC, Expanding Its Market Reach to Global Pharmaceutical Manufacturing Sector
September 5, 2007
- Lundbeck and Takeda Form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders
- Ventana Medical Systems Acquires Spring BioScience
- Bayer Intends to Delist from the New York Stock Exchange
- Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
- Public Communication - Health Canada Endorsed Important Safety Information on Ketek(telithromycin)
- Colorcon Acquires Pharmaceutical Excipients and Coating Division of Chr. Hansen, Inc.
- Forest Laboratories Announces Federal Appeals Court Upholds Lexapro Patent Decision
- Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets; Novartis' Motion for Preliminary Injunction Denied
September 6, 2007
- AstraZeneca Launches and Prices a $6.9 Billion Bond Issue
- FDA Approves First Generic Versions of Coreg
- Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
- China Aoxing Pharmaceutical Company Receives Government Approval for Increased Ownership of its Main Operating Subsidiary, Hebei Aoxing; Amends Terms of the Acquisition Agreement
- American Oriental Bioengineering Completes Acquisition of Changchun Xinan Pharmaceutical Group Company Ltd.
- Biogen Idec Announces Strategic Updates at Investor Meetings
- Elliott 'Extremely Dissatisfied' With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
- Youth Drug Use at a Five Year Low, New Survey Shows
- New Jersey High Court Denies Nationwide Class-Action Status to Insurance Companies Seeking Vioxx Reimbursements
- CDC Report Shows Largest One-Year Increase in Youth Suicide Rate in 15 Years
September 7, 2007
- Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
- Ablynx and Boehringer Ingelheim Announce Major Global Strategic Alliance to Discover, Develop and Commercialize Novel Nanobody Therapeutics
- Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
- Sens. Grassley, Kohl Say Public Should Know When Pharmaceutical Makers Give Money to Doctors
- Enzo Biochem, Inc. Files Appeal to Federal Court Decision
- Publicis Groupe Announces Intention to Delist its American Depository Receipts (ADRs) from the New York Stock Exchange and to Deregister and Terminate its Reporting Obligations under the U.S. Securities Laws
- Pozen/AstraZeneca Announce Start of the PN 400 Phase III Program
- Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics
- Novartis to Defend Its Intellectual Property Rights for Famvir Despite an "at-risk" Generic Launch in US
- Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
- This Week, Pharma Bloggers Criticize Merck’s Vioxx Studies, Pfizer’s Third Breach of Confidential Data, and the Bush Administration
September 10, 2007
- Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
- MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist
- BioVascular, Inc. Merges with Revitus and Acquires First-In-Class Platelet Count Reducer
- Repligen Announces Settlement with ImClone In Erbitux Lawsuit
- United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
- Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet
- $52.5 Million Settlement Against Sepracor Inc. Approved
- Pfizer Issues a Dear Healthcare Professional Letter to Inform Healthcare Professionals of the Presence of Ethyl Methanesulfonate in Viracept
- Statement by Commissioner von Eschenbach on the Release of the Strategic Framework Document on Import Safety
September 11, 2007
- Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
- Evotec Sells its Chemical Development Business to Aptuit for GBP 31.5m (approx. EUR 46.4m; US$ 63.9m) in Cash
- Alcon Waives Minimum Acceptance Condition for WaveLight AG
- Biovail Says Settlement With Maris, BAS Expected to Be Helpful in Suit Against Hedge Funds and Others
- Merck & Co., Inc. Announces Completion of NovaCardia, Inc. Acquisition
- Aptuit to Acquire CPD Business of Evotec AG
- Vote for the Most Admired Pharmaceutical, Biotechnology, and Specialty Companies
- Adverse Drug Events Reported to FDA Appear to Have Increased Markedly
- FDA - MedWatch - Rocephin (ceftriaxone sodium) - Dear Healthcare Provider Letter Clarifying Potential Risk Associated With Concomitant Use Of Rocephin With Calcium Containing Products
- GlaxoSmithKline Responds to JAMA Articles
September 12, 2007
- Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
- FDA Advisory Panel to Review Medtronic's Endeavor Drug Eluting Stent on October 10
- Publicis Groupe Acquires Wcube, France’s Top Independent Digital Agency
- Flamel Technologies Announces Medusa License Agreement with Wyeth Pharmaceuticals
- Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
September 13, 2007
- Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
- Angiotech Receives Favourable Patent Decision from New Zealand's Intellectual Property Office
- First Consulting Group (FCG) Announces Sale of FirstGateways Business to MedPlus, Inc.
- FDA To Continue Its Review of Requests for Release of Clinical Hold on Alvimopan (Entereg)
- FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol
- New Licence for Cubicin (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
- Canadian Court Finds Infringement of Lipitor Crystal Form Patent
- IFRS Information - First Half of 2007
- Physicians Urge Kennedy, Dodd to Support Curb on Financial Conflicts of Interest on FDA Advisory Committees
- Cephalon Reinforces Important Prescribing and Dosing Information for Fentora
September 14, 2007
- Novartis Completes Agreement with Bayer Schering Related to Betaseron Rights and Manufacturing
- Sanofi-aventis Initiates Research Collaboration in China in the Cancer Stem-Cell Field
- Bayer Completes Acquisition of U.S. Biologics Manufacturing Facility from Novartis
- Bayer Completes Acquisition of U.S. Biologics Manufacturing Facility from Novartis
- Four Leading Independent Proxy Advisory Firms Recommend Bausch & Lomb Shareholders Vote ''For'' Transaction with Warburg Pincus
September 17, 2007
- Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth
- FDA Approves Levaquin Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
- Depomed Announces Reduction in Force
- AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks With ADHD Medications
- AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks With ADHD Medications
- United BioSource Acquires Caro Research, Leader in Simulation Modeling
- LabPas CT Selected by Qualia Clinical Services for Phase I Clinical Trials
September 18, 2007
- FDA Clears Genetic Lab Test for Warfarin Sensitivity
- FDA Alerts Healthcare Professionals to Deaths Linked to Haloperidol
- FDA - MedWatch - Haloperidol Marketed As Haldol, Haldol Decanoate, And Haldol Lactate Get New Warnings And Revised Prescription Information
- Pharmaceutical Marketers to Spend $2.2 Billion Online in 2011
- LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
- GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
- Roche Announces Tamiflu Will be in Ample Supply for 2007-2008 Flu Season
- Merck & Co., Inc. Response to Today's New York Medicaid Suit
- N.Y. AG Cuomo, Mayor Bloomberg Sue Maker of Vioxx for Hiding Drug’s Risks
September 19, 2007
- Bavarian Nordic Strengthens its Commercial Organisation and Updates on Pipeline Progress
- Esprit Pharma, Inc. to Be Aquired by Allergan, Inc.
- NJAG Milgram Announces Task Force to Study the Influence of Gift-Giving to Physicians by Pharmaceutical Manufacturers, Medical Device Makers
- Orexigen Announces Settlement Agreement with Eisai
- Alnylam Announces the Termination of its Collaboration with Merck & Co., Inc.
- Baby Boomers Want Control of Their Own Health and Actively Seek out Information from Multiple Sources to Help Make Decisions
September 20, 2007
- Ventana Responds to Third Extension of Roche's Unsolicited Tender Offer
- Sanofi pasteur First Manufacturer to Ship Doses of Influenza Vaccine for the 2007-2008 Season
- Roche Extends Tender Offer for Ventana
- Karo Bio Development of Clinical Candidate LXR-623 Discontinued
- PSI Brings its Pioneering Efforts to a Close
- New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
September 21, 2007
- European License for Roche HIV Drug Viracept Recommended for Reinstatement
- FDA Sends Kunshan Chemical & Pharmaceutical Company Letter About its Facilities
- Statement by FDA Commissioner Andrew C. von Eschenbach on Passage of FDA Amendments Act of 2007 (FDAAA)
- Exelixis Research Collaboration With Bristol-Myers Squibb Extended
- Bausch & Lomb Shareholders Approve Merger with Affiliates of Warburg Pincus
- Court Rules for Pfizer in Patent Infringement Case on Neurontin
- Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate
- Biomax Informatics AG Acquires Data Mining Business from eudaptics software gmbh
September 24, 2007
- Teva Provides Update On Generic Neurontin Litigation
- Biogen Idec Announces Research Collaboration with Johns Hopkins Brain Science Institute
- Bristol-Myers Squibb to Acquire Adnexus Therapeutics
- Elixir Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
- US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
- Dyadic Announces Termination of Employment of its President and CEO, Mark A. Emalfarb
- Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
- MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
- New Brunswick Scientific Completes Merger Transaction with Eppendorf
September 25, 2007
- Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
- GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
- Aranesp DAHANCA 10 Study Results Presented at ECCO Annual Meeting
- Panacos Announces Management Changes
- TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
- Impact of discontinuation of Merck HIV study on Crucell's prospects
- Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
- Barr Confirms Patent Challenge of Uroxatral
September 26, 2007
- Palatin Technologies Announces Reduction of Workforce
- Depression Intervention in Workplace Increases Employee Productivity 2.6 Hours a Week
- Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
- Verispan's Vector One: Antidepressant Prescribing Decreases in Teenagers
- Exclusive Agreement Announced Between Quidel Corporation and Roche Pharma AG
- FDA Warns of Potential Serious Side Effects with Breakthrough Cancer Pain Drug
September 27, 2007
- FDA, Leading Pharma Companies Launch Global Collaboration to Research Genetic Markers Linked to Drug Safety
- PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
- Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp
- Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
- Taisho and BrainCells Signed a License Agreement for Taisho's New Drug Candidates of CNS Indications
- PhRMA Statement on Enactment of FDA Legislation
- Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
September 28, 2007
- Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
- Celera Announces Clinical Milestone Payment from Merck
- Novartis and Massachusetts Institute of Technology in New Partnership Aimed at Transforming Pharmaceutical Manufacturing
- Eisai Announces Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
- Alcon Gains 76.9 Percent of WaveLight Shares and Will Move Forward with Acquisition
- Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
- OIG Releases Report of FDA’s Oversight of Clinical Trials, Concludes Improvement of Information Systems and Processes is Needed
- Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
- Canadian Federal Court Upholds Viagra Patent
- FDA Takes Action to Stop Marketing of Unapproved Hydrocodone Products
- Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
- FDA-MedWatch -Gadolinum Based Contrast Agents: Dear Healthcare Professional Letter Issued Regarding Boxed Warning And Revisions to Warning Section of Prescribing Information
